Prostate cancer is the leading male cancer worldwide. There remains a controversy\nas to which patients have indolent disease and which patients present\nan aggressive disease needing treatment with intent to cure. Because of quality\nof life impairment associated with treatment by radiation or surgery, active\nsurveillance (AS) is a valid management option to avoid or differ aggressive\ntreatment. Traditionally, AS was reserved for men with low risk prostate cancer,\nhowever intermediate risk patients are more and more found in AS cohorts.\nThe aim of this review is to describe the place of AS in intermediate\nrisk patients and the perspectives offered by such a treatment modality.
Loading....